Mingorance C, Rodrguez-Rodrguez R, Justo ML, de lvarez Sotomayor M, Herrera MD, Mingorance C, Rodrguez-Rodrguez R, Mara Luisa Justo M, de lvarez Sotomayor M, Mara Dolores Herrera M, Profesor Garca Gonzlez no, DOVE Medical Press Ltd
doi:10.1056/NEJMoa2032183 Pi-Sunyer X, Astrup A, Fujioka K, et al
May support evaluation Common Eligibility Factors BMI of 30 or greater BMI of 27 or greater with a related health condition Prior lifestyle efforts without durable results Ability to attend monitoring and report symptoms Willingness to support nutrition, movement, and maintenance Needs more review Reasons to Avoid, Delay, or Modify Treatment Pregnancy, planned pregnancy, or breastfeeding Personal or family history of medullary thyroid carcinoma or MEN2 for Wegovy/Zepbound Severe gastroparesis or significant gastrointestinal disease Active or unstable eating disorder Prior serious allergy to the medicine Inability to maintain fluid or nutrition Medication interactions or uncontrolled illness These medicines are not intended for cosmetic weight loss The goal is treatment of obesity or clinically significant overweight-related risknot rapid loss of a few pounds for an event
Its versatility allows it to be used in a variety of procedures, ranging from intramuscular to intravenous injections
Proceedings of the National Academy of Sciences of the United States of America , 89 , 86418645 (United States, 1992)